-
2024-516843-15-00
5
2015-11-23
Non-squamous Non-small Cell Lung Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-506524-82-00
5
2015-10-21
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
-
2024-515283-31-00
6
2015-07-30
This study is designed to accept patients with varied disease origins,
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2024-511640-11-00
5
2014-05-15
Follicular lymphoma
-
2024-512413-40-00
4
2013-03-08
Chronic myeloproliferative neoplasm
-
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2024-519549-31-00
5
2025-09-05
Invasive meningococcal disease (IMD)
-
2024-519856-94-00
4
2025-08-18
Cystic fibrosis
-
2023-505801-17-00
2
2025-01-15
Haemophilia A
-
2023-504964-41-00
7
2024-11-06
Idiopathic pulmonary fibrosis
-
2023-508474-29-00
4
2024-10-30
Dermatitis, Atopic
-
2023-509197-35-00
5
2024-10-17
Thyroid Eye Disease (TED)
-
2024-511360-87-00
5
2024-10-02
hidradenitis suppurativa (HS)
-
2023-505797-15-00
5
2024-09-13
SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
-
2023-508395-11-00
4
2024-09-10
idiopathic pulmonary fibrosis
-
2023-510249-79-00
4
2024-09-10
Progressive pulmonary fibrosis (PPF)
-
2023-508170-28-00
4
2024-08-07
alcohol-related liver disease
-
2023-505851-33-00
5
2024-07-29
Dravet Syndrome
-
2023-506185-31-00
10
2024-07-18
Idiopathic pulmonary fibrosis (IPF)
-
2023-509001-76-00
5
2024-07-01
Asthma
-
2023-506210-40-00
5
2024-06-28
Heart Failure due to Systemic Left Ventricular Systolic Dysfunction